Skip to main content
SpringerLink
Log in

Analisi di costo-efficacia della vaccinazione universale in Italia con il vaccino Rix4414 contro i rotavirus

Cost-effectiveness of universal rotavirus vaccination with Rix4414 in Italy

  • Published:
PharmacoEconomics Italian Research Articles

Summary

Objectives: Rotavirus (RV) is the most common etiological agent of gastroenteritis in children. The oral vaccine Rix4414 was recently commercialized in Italy for prevention of RV infections. The health outcomes and the economic impact of a national RV immunization program were assessed.

Design: A Markov model simulated the flow of a birth cohort on RV disease burden and costs up to age 5, comparing a RV vaccination programme with no vaccination. Lifetime cost-effectiveness for the national healthcare system (NHS) and the society (S) with a benchmark of 50,000 €/QALY was analysed.

Main results: Disease’s medical direct costs exceeded 30 million €/year, while indirect costs approached 112 million €/year. A routine, universal RV immunization program, for a birth cohort of 550,000 children, would prevent 80% of RV diarrhoea, 97% of severe RV cases, 87% of medical consultations and 98% of hospitalizations. In the NHS perspective, the incremental cost/QALY would be € 14,829 and it would decrease to € −17,030 (cost-saving) in the S perspective. In the private market scenario, the incremental cost/QALY (€ 24,687) would remain far below the threshold.

Conclusion: A national immunization program with Rix44141 in Italy would be cost-effective both from the S and the NHS perspective.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Bibliografia

  1. Parashar U, Gibson C, Breese J, Glass R. Rotavirus and severe childhood diarrea. Emerg Infect Dis 2006; 12: 304–6

    Article  PubMed  Google Scholar 

  2. Albano F, Bruzzese E, Bella A, et al. Rotavirus and not age determines gastroenteritis severity in children: a hospital-based study. Eur J Pediatr 2007; 166: 241–7

    Article  PubMed  Google Scholar 

  3. Van Damme P, Giaquinto C, Huet F, et al. Multicenter prospective study of the burden of rotavirus acute gastroenteritis in Europe, 2004–2005: the REVEAL study. J Infect Dis 2007; 195: S4–S16

    Article  PubMed  Google Scholar 

  4. Forster J, Guarino A, Parez N, et al. Hospital-based surveillance to estimate the burden of rotavirus gastroenteritis among European children aged <5 years. 25th Annual Meeting of the European Society for Pediatric Infectious Diseases, Porto, Portugal, May 5–6, 2007. Abstract consultabile all–URL: http://www.kenes.com/espid

  5. Biermann KP, Neri S, Reali MF, et al. Incidence of nosocomial rotavirus infections in a pediatric hospital over a 3-year period. Minerva Pediatr 2006; 58: 477–82

    PubMed  CAS  Google Scholar 

  6. Ruggeri FM, Declich S. Rotavirus infection among children with diarrhoea in Italy. Acta Paediatr 1999; 88: 66–71

    Article  CAS  Google Scholar 

  7. Marocco A, Assael B, Gabutti G, et al. Ricoveri per enterite da Rotavirus in Italia valutati mediante analisi delle Schede di Dimissione Ospedaliera negli anni 2001–2003. Igiene e Sanità Pubblica 2006; 62: 215–24

    PubMed  Google Scholar 

  8. Soriano-Gabarrò M, Mzrukowic J, Vesikari T, et al. Burden of rotavirus disease in European Union Countries. Ped Infect Dis J 2006; 25: S7–S11

    Article  Google Scholar 

  9. Giambi C, Tozzi A, Ciofi degli Atti M. Approfondimento sui rotavirus. EpiCentro 2007, Numero 15 Marzo. Consultabile all’URL: http://www.epicentro.iss.it/problemi/rotavirus/

  10. Rotarix® — Riassunto delle Caratteristiche di Prodotto — ultimo aggiornamento: dicembre 2007

  11. Ruiz-Palacios G, Perez-Schael I, Velazquez R, et al. Safety and efficacy of attenuated vaccine against rotavirus gastroenteritis. N Engl J Med 2006; 354: 11–2

    Article  PubMed  CAS  Google Scholar 

  12. Vesikari T. RLX44141 is highly efficacious in Europe. 24th Annual Meeting of the European Society for Pediatric Infectious Diseases, Basel, Switzerland, May 3–5, 2006. Abstract consultabile all’URL: http://www.kenes.com/espid

  13. Melliez H, Boelle P-Y, Baron S, et al. Morbidity and cost of rota-virus infections in France. Med Mal Infect 2005; 35: 492–9

    Article  PubMed  CAS  Google Scholar 

  14. Standaert B, Marocco A, Banfi F, Marchetti F. Valutazione del rapporto costo-efficacia della vaccinazione contro i rotavirus nel contesto italiano. Atti del 42° Congresso Nazionale Società Italiana di Igiene e Medicina Preventiva. Panorama della Sanità 2006; 39 (Suppl.): 333

    Google Scholar 

  15. Giaquinto C, Van Damme P, Uet F, et al. Clinical consequences of rotavirus acute gastroenteritis in Europe, 2004–2005: the REVEAL study. J Infect Dis 2007; 195: S26–35

    Article  PubMed  Google Scholar 

  16. Riva E, Banderali G, Agostoni C, et al. Factors associated with initiation and duration of breastfeeding in Italy. Acta Paediatr 1999; 88: 411–5

    Article  PubMed  CAS  Google Scholar 

  17. Faldella G, Di Comite A, Marchiani E, et al. Breastfeeding duration and current neonatal feeding practices in Emilia Romagna, Italy. Acta Paediatr Suppl. 1999; 88: 23–6

    Article  PubMed  CAS  Google Scholar 

  18. Thiry N, Beutels P, Tancredi F, et al. An economic evaluation of varicella vaccination in Italian adolescents. Vaccine 2004; 22: 3546–62

    Article  PubMed  Google Scholar 

  19. Fontana M, Zuin G, Cancheri P, et al. Costs associated with outpatient diarrhoea in infants and toddlers: a nationwide study of the Italian Society of Pediatric Gastroenterology and Hepatology (SIGEP). Dig Liver Dis 2004; 36: 523–7

    Article  PubMed  CAS  Google Scholar 

  20. Laporta T, Di Scioscio V, Canini R, et al. Analisi costo-efficacia e valutazione della tecnologia in radiologia. OdV — Ospedali della vita 2006; 18: 1–11

    Google Scholar 

  21. Tariffe delle prestazioni di assistenza ospedaliera per acuti erogate in regime di ricovero ordinario e diurno ex D.M. 30.06.1997 espresse in Euro. Consultabile all’URL: http://www.ministerosalute.it/programmazione/normativa/sezNormativa.jsp?label=tar

  22. Gianino E, Mastretta P, Longo A, et al. Incidence of nosocomial rotavirus infections, symptomatic and asymptomatic, in breastfed and non-breast-fed infants. J Hosp Infect 2002; 50: 13–7

    Article  PubMed  CAS  Google Scholar 

  23. Istituto Italiano di Statistica (ISTAT). Consultabile all’URL: http://www.demo.istat.it

  24. Martin A, Cortell S. Estimating utility in rotavirus gastroenteritis in children under five in the UK. Contributed Poster Presentations. Value Health 2006; 9: A208–A393

    Google Scholar 

  25. Legge 17 agosto 1974, n. 386, art. 9: “Norme per l’estinzione dei debiti degli enti mutualistici.”

  26. Rheingans R, Heylen J, Giaquinto C. Economics of rotavirus gastroenteritis and vaccination in Europe: what makes sense? Ped Infect Dis J 2006; 25 (Suppl. 1): S48–S55

    Article  Google Scholar 

  27. Greiner W, Lehmann K, Earnshaw S, et al. Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ 2006; 7: 290–6

    Article  PubMed  CAS  Google Scholar 

  28. Eichler H, Kong S, Gerth W, et al. Use of cost-effectiveness analysis in health care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 2004; 7: 518–28

    Article  PubMed  Google Scholar 

  29. Ravasio R, Lucioni C, Chirico G. Costo-efficacia di palivizumab versus non profilassi nella prevenzione delle infezioni da VRS nei bambini pretermine, a diversa età gestazionale. Pharmaco Economics-Italian Research Articles 2006; 8: 105–17

    Google Scholar 

  30. Van Damme P. Evidence-based recommendations for the use of rotavirus vaccine in Europe. 25th Annual Meeting of the European Society for Pediatric Infectious Diseases, Porto, Portugal, May 5–6, 2007. Abstract consultabile all’URL: http://www.kenes.com/espid

  31. Piano Nazionale Vaccini 2005–2007. Gazzetta Ufficiale del 14-4-2005

  32. Colombo GL, Serra G, Morlotti L, Fara GM. The role of economic evaluation for the implementation of vaccination strategies. Annali di Igiene 2005; 17: 479–90

    PubMed  CAS  Google Scholar 

  33. Marocco A, Bamfi F, Marchetti F. Analisi di “budget impact” della vaccinazione universale anti-rotavirus in Italia con il vaccino Rix4414. Atti della X Conferenza Nazionale di Sanità Pubblica. Pisa, 14–16 ottobre 2007. Poster 169: 291

  34. De Marco G, Di Caro S, Guarino A. Il vaccino anti-rotavirus. In: Ugazio AG e Guarino A, editors. Le vaccinazioni per la pratica pediatrica. Pisa: Pacini Editore, 2006: 249–56

    Google Scholar 

  35. Raes M, Aerssens P, Alliet P, et al. Rotavirus gastroenteritis epidemiological data from a regional hospital in Belgium. Eur J Pediatr 2007; Epub ahead of print February 9, 2007

    Google Scholar 

  36. Marchetti F, Assael B, Gabutti G, et al. I database regionali ICD9-CM costituiscono uno strumento utile ed efficace per stimare i ricoveri ospedalieri prima e dopo l’introduzione della vaccinazione anti-rotavirus in Italia. Atti della X Conferenza Nazionale di Sanità Pubblica. Pisa, 14–16 ottobre 2007. Poster 168: 291

  37. Kolsen Fisher T, Viboud C, Parashar U, et al. Hospitalizations and deaths from diarrhea and rotavirus among children <5 years of age in the United States, 1993–2003. J Infect Dis 2007; 195: 1117–25

    Article  Google Scholar 

  38. Jit M, Pebody R, Chen M, et al. Estimating the number of deaths with rotavirus as a cause in England and Wales. Hum Vaccin 2007; 3: 23–6

    Article  PubMed  Google Scholar 

  39. Tuker AW, Haddix A, Bresee J, et al. Cost-effectiveness analysis of a rotavirus immunization program for the United States. JAMA 1998; 279: 1371–6

    Article  Google Scholar 

  40. Giaquinto C, Callegaro S, Andreola B, et al. Costi della gastroenterite da rotavirus acquisita in comunità in età pediatrica a Padova in Italia. Pharmacoeconomics-Italian Research Articles 2007; 9: 103–11

    Google Scholar 

  41. Largeron N, Trichard M, Fargier HM, et al. Cost-effectiveness analysis of rotavirus vaccination programme in the UK. ISPOR Annual European Congress, October 28–31, 2006 Copenhagen, Denmark. Poster PGI8

  42. Littmann M, Huelsse C, Burkowitz J, et al. Economic evaluation of a universal rotavirus vaccination programme in Germany. 25th Annual Meeting of the European Society of Pediatric Infectious Diseases, Porto, Portugal, May 2–5, 2007. Consultabile all’URL: http://www.kenes.com/espid/program/ViewAbstract.asp

  43. Huet F, Langeron N, Trichard M, et al. Burden of pediatric rotavirus gastroenteritis and potential benefits of a universal rotavirus vaccination programme with Rota Teq in France. Vaccine 2007; 25: 6348–58

    Article  PubMed  Google Scholar 

  44. Lee BP, Azimi P, Staat MA, et al. Nonmedical costs associated with rotavirus disease requiring hospitalization. Ped Infect Dis J 2005; 24: 984–8

    Article  Google Scholar 

  45. Liddle M, Burgess M, Gwendolyn G, et al. Rotavirus gastroenteritis: impact on young children, their families and the health care system. Med J Aust 1997; 167: 304–7

    PubMed  CAS  Google Scholar 

  46. Jit M, Edmunds WJ. Evaluating rotavirus vaccination in England and Wales. Part II: The potential cost-effectiveness of vaccination. Vaccine 2007; 25: 3971–9

    Article  PubMed  CAS  Google Scholar 

  47. Widdowson MA, Meltzer ML, Zhang X, et al. Cost-effectiveness and potential impact of rotavirus vaccination in the United States. Pediatrics 2007; 119: 684–97

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Health-Economics Department, GlaxoSmithKline Biologicals, Rixensart, Belgio

    B. Standaert

  2. Direzione Medica, GlaxoSmithKline S.p.A, Via A. Fleming 2, 37135, Verona, Italia

    A. Marocco &  Federico Marchetti

  3. Ospedale Regionale Fibrosi Cistica, Verona, Italia

    B. Assael

  4. Dipartimento di Medicina Clinica e Sperimentale, Università di Ferrara, Italia

    G. Gabutti

  5. Dipartimento di Pediatria, Università di Napoli, Italia

    A. Guarino

  6. Dipartimento di Sanità Pubblica, Università di Bari, Italia

    P. L. Lopalco

  7. Dipartimento di Sanità Alimentare e Animale, Istituto Superiore di Sanità, Roma, Italia

    F. M. Ruggeri

  8. Istituto di Malattie Infettive, Università di Palermo, Italia

    L. Titone

  9. Unità di Epidemiologia, Ospedale Bambin Gesù, Roma, Italia

    A. Tozzi

  10. Pediatra di famiglia, Firenze, Italia

    G. Vitali Rosati

  11. Dipartimento di Sanità Pubblica, Università di Torino, Italia

    C. Zotti

  12. Dipartimento di Sanità Pubblica, Università di Roma Tor Vergata, Italia

    E. Franco

Authors
  1. B. Standaert
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Marocco
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B. Assael
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. Gabutti
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Guarino
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. P. L. Lopalco
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Federico Marchetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. F. M. Ruggeri
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. L. Titone
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. A. Tozzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. G. Vitali Rosati
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. C. Zotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. E. Franco
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Federico Marchetti.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Standaert, B., Marocco, A., Assael, B. et al. Analisi di costo-efficacia della vaccinazione universale in Italia con il vaccino Rix4414 contro i rotavirus. Pharmacoeconomics-Ital-Res-Articles 10, 23–35 (2008). https://doi.org/10.1007/BF03320638

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03320638

Search

Navigation